Uniphore Accelerates Expansion Across Europe
PALO ALTO, Calif. & LONDON, June 10, 2025--(BUSINESS WIRE)--Uniphore, the Business AI Company, today announced a significant expansion across Europe, accelerating its commitment to the region through new customer adoption, partner momentum, product launches, and organizational investment.
The announcement coincides with the release of the Uniphore Business AI Cloud, announced during the AI Leadership Summit held yesterday in London—an exclusive gathering of media, industry leaders, and Uniphore customers exploring the future of agentic AI in Europe. Attendees included executives from ResultsCX, Konecta, KPMG, and Rowan Curran, Principal Analyst at Forrester, who shared perspectives on how enterprises are scaling AI from isolated pilots to business-critical systems that drive measurable outcomes across customer experience, marketing, operations and more.
A Platform Built for Europe's AI Mandate
As enterprise adoption of AI accelerates across Europe, CIOs and Line of Business Leaders face growing pressure to deliver solutions that align with the EU's AI Act. Uniphore's Business AI Cloud delivers on these requirements through a sovereign, composable, and secure platform that allows enterprises to activate AI across voice, video, text, structured and unstructured data — without compromising privacy or control.
With generative AI projected to grow at 55 percent annually in Europe and AI spending expected to exceed $133 billion in the region by 2028, European CIOs are under pressure to move beyond experimentation and deliver business-ready AI that is secure, compliant and operational at scale. Uniphore's Business AI Cloud is built to meet this demand, supporting the CIO mandate to operationalize AI across workflows while meeting strict data governance, privacy and ethical standards defined in the EU AI Act and other regulatory frameworks.
Fall 2025: Uniphore Marketing AI CDP Launches in EMEA
Uniphore will formally launch its Marketing AI CDP and Marketing Agents, part of the Business AI Suite, in the European market this fall. Built for enterprise marketers navigating complex privacy landscapes and fragmented customer data, the solution helps teams activate insights and deploy agentic marketing workflows — without requiring data movement or custom engineering.
Among Uniphore's newest customers in the region is Hearst UK, a leading media organization embracing AI to drive marketing automation and personalized engagement.
"We've been really pleased with the flexibility and composability of the Uniphore CDP," said Krishan Gandhi, Senior Director of Data Engineering & Analytics at Hearst UK. "As we continue to evolve our customer data strategy, we're excited to see how Uniphore's Marketing Agents and complete AI platform will help us better engage audiences, streamline workflows, and drive more impactful marketing outcomes."
The Uniphore Business AI Suite includes Marketing AI, a CDP with pre-built agents purpose-built for enterprise marketers, including the Product Knowledge Agent (now generally available), which answers user questions in real time using indexed product documentation; the Platform Search Agent, launching in Summer 2025, which enables semantic search across audiences, attributes, and platform components; and the Audience Segmentation Agent, also arriving this summer, which allows marketers to build audience cohorts from plain-English prompts using both rule- and outcome-based logic. Together, these agents help enterprises accelerate first-party data activation while meeting GDPR compliance requirements out of the box.
Momentum with Konecta Drives Scaled Transformation
Uniphore also continues to deepen its relationship with global BPO leader Konecta, following the strategic partnership announced in late 2023. The companies are jointly scaling AI-led contact center transformation across Europe — automating quality monitoring, enabling real-time agent guidance and delivering measurable outcomes for telecom and financial services leaders.
"With Uniphore, we're building an agentic AI factory, designed to rapidly create, deploy and orchestrate AI agents across our customer environments," said Oscar Vergé, chief AI deployment officer at Konecta. "The platform's agent builder, orchestration engine and support for both prebuilt and custom agents allow us to agentify critical workflows for each client, from customer service to back-office automation. This isn't just AI adoption — it's real transformation at enterprise scale."
Konecta leaders joined Uniphore onstage at the AI Leadership Summit in London to discuss deployment momentum and share learnings on production-grade enterprise AI.
Growing the Team and Leadership Across EMEA
Uniphore has significantly grown its presence in the region, expanding its team across sales, engineering, and customer success. The company now operates from a dedicated London office as well as an office in Valencia, Spain and is actively engaged in deployments across key markets throughout EMEA.
To support this growth, Jeremy Keefe has joined as Vice President of Sales, EMEA, bringing decades of enterprise software leadership to Uniphore's regional go-to-market strategy.
About Uniphore
Uniphore is the Business AI company. Our sovereign, composable, and secure AI platform connects enterprise data, fine-tunes AI models and deploys agentic AI across the enterprise. We empower every worker to boost productivity and help businesses grow faster, operate smarter and reduce costs. Trusted by more than 1,500 businesses globally, and recognized on the Deloitte Fast 500, Uniphore delivers on the promise of AI as a transformative force for business.
Learn more about Uniphore's Business AI Cloud and enterprise AI solutions at www.uniphore.com. For insights, updates and thought leadership, explore our blog or follow us on LinkedIn.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250610372448/en/
Contacts
Media Contact: Tim HarrisDirector, Public Relationstim.harris@uniphore.com
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
Government to take control of Speciality Steel after insolvency
The government has taken control of the UK's third largest steelworks in a bid to save 1,450 jobs at the site. The high court confirmed on Thursday that Speciality Steel – previously part of Sanjeev Gupta's Liberty Steel business – would face a compulsory liquidation. The operation, which has plants in Rotherham and Stocksbridge in South Yorkshire, will be placed into the hands of the Official Receiver and special managers from advisory firm Teneo. Ongoing wages and costs to keep the plant running will be covered by the Government until a buyer is found. However, bosses at Speciality Steel said the move to wind up the business is 'irrational'. Jeffrey Kabel, chief transformation officer said: 'The decision to push Speciality Steel UK into compulsory liquidation, especially when we have support from the world's largest asset manager to resume operations and facilitate creditor recovery is irrational. 'The plan that GFG (Sanjeev Gupta's parent business) presented to the court would have secured new investment in the UK steel industry, protecting jobs and establishing a sustainable operational platform under a new governance structure with independent oversight. 'Instead, liquidation will now impose prolonged uncertainty and significant costs on UK taxpayers for settlements and related expenses, despite the availability of a commercial solution.' GFG said it will put forward a bid to retake control of the business alongside debt and equity partners and present this to the Official Receiver. A Government spokesperson said: 'We know this will be a deeply worrying time for staff and their families, but we remain committed to a bright and sustainable future for steelmaking and steel making jobs in the UK. 'It is now for the independent Official Receiver to carry out their duties as liquidator, including ensuring employees are paid, while we also make sure staff and local communities are supported.' UK Steel director general Gareth Stace said: 'UK Steel welcomes the Government's recognition of the importance of the Liberty Speciality Steel assets and hopes that a new owner is found quickly and can inject the investment and working capital required to return production volumes to previous levels. 'The assets produce high quality, specialist steels that serve high value markets. 'The low production levels of recent years have left significant holes in the domestic supply chain that have been filled by imports. 'We hope to see these holes quickly filled by UK-made steel.'
Associated Press
25 minutes ago
- Associated Press
Dr. Nikola Cihoric Redefines Clinical Research Through Innovation, Technology, and Data
ZURICH, SWITZERLAND, August 21, 2025 / / -- Bridging Medicine, Research, and Technology for Patient-Centric Solutions Dr. Nikola Cihoric, founder and visionary behind Wemedoo AG, is redefining clinical research by merging technology, innovation, medicine, and data into a seamless ecosystem that empowers healthcare professionals and researchers alike. With over 15 years of experience in radiation oncology and a deep commitment to clinical data standardization, Dr. Cihoric is setting a new standard in the way clinical trials are conducted worldwide. A Vision Born from Real Clinical Challenges Wemedoo was born from Dr. Cihoric's firsthand frustration with fragmented healthcare systems and inefficient clinical workflows. 'I observed the paper world and sloppy digitalization that slowed treatment delivery and overburdened medical staff,' he explains. His focus on data standardization and cross-sector collaboration led to the development of an early prototype, oopus (initially SmartOncology), which received support from the Swiss Cancer Foundation. Building on this experience, Wemedoo developed its unique approach, which eliminates silos, enhances transparency, and gives researchers full control across the clinical data lifecycle. Learn more about Dr. Cihoric's vision in the Xraised interview. Transforming Clinical Trials Through Technology Unlike traditional clinical trial solutions that rely on multiple disconnected systems, Wemedoo's oomnia system integrates EDC, CTMS, eTMF, eConsent, RTSM, and advanced reporting in a single, unified, and interoperable environment. This approach eliminates costly integrations, reduces errors, and ensures data consistency across every stage of a trial. 'By using technology to unify processes, we save time, reduce errors, and provide real-time insights for clinicians and researchers,' Dr. Cihoric notes. 'Our no-code configuration also allows rapid adaptation to evolving trial requirements, ensuring flexibility without compromising quality.' Ethical AI and Data-Driven Innovation Wemedoo integrates AI into oomnia practically and responsibly, focusing on automating processes where it delivers immediate value without unnecessary risks, essential in a highly regulated industry. Their work is guided by explainability and transparency, from AI-driven risk assessment tools for protocol design to semantic mapping engines that cut data processing timelines from months to days. Wemedoo is also exploring agentic AI to support operational decision-making, always with a 'man-in-control' philosophy to ensure accountability. What makes this possible is oomnia's semantic foundation, structured data, common data elements, and standard vocabularies, which keep outcomes reproducible, interpretable, and aligned with regulatory frameworks. Beyond technology, Wemedoo collaborates with public institutions and publish in peer-reviewed journals, reinforcing their belief that AI is only meaningful if it strengthens trust, transparency, and data integrity. Balancing Clinical Practice and Product Development Despite his active role at Wemedoo, Dr. Cihoric continues to work in a leading academic hospital. This dual role allows him to translate real-world clinical challenges into actionable system improvements. 'Being close to patients and clinical teams keeps me grounded in reality, ensuring that our technology delivers tangible benefits,' he says. Long-Term Vision for Clinical Research Looking ahead, Dr. Cihoric aims to remove barriers between clinical practice and research, investing in education, resources, and stakeholder alignment to ultimately improve patient outcomes. 'The goal is to create a future where innovation, technology, and real-world data converge seamlessly to benefit patients worldwide,' he asserts. About Dr. Nikola Cihoric Dr. Nikola Cihoric is a radiation oncologist, researcher, and founder of Wemedoo AG, with expertise in clinical data standardization, AI integration, and oncology innovation. He has published over 35 scientific papers and actively contributed to international standards groups such as mCODE, CodeX, HL7/FHIR, and CDISC. For more information on Dr. Nikola Cihoric and Wemedoo's groundbreaking work, visit Wemedoo and explore insights from Xraised ( ). Media and Business Inquiries General contact: [email protected] Business development: [email protected] Website: LinkedIn: Wemedoo AG. Gianmarco Giordaniello Xraised email us here Visit us on social media: LinkedIn Instagram X Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Associated Press
25 minutes ago
- Associated Press
A Hair Transplant Journey Starting in the UK, Completed in Turkey
ISTANBUL, TURKEY / ACCESS Newswire / August 21, 2025 / Established in Turkey, Esteworld now offers face-to-face consultations in London and continues its operations in its state-of-the-art hospitals in Istanbul. This combines clinical quality with the value that has made Turkey a global destination. Post-procedure care is provided in the country where the procedure was performed. August 20, 2025 Esteworld announced the launch of a new office in London, marking the next step in the brand's international growth. Having built its reputation by delivering hair transplant in Turkey services, Esteworld is expanding access for UK and European patients who want local guidance before and after surgery, with the procedure itself performed by experienced teams in Istanbul. 'Patients told us they want two things: the clinical excellence and value associated with Turkey, and the convenience of a local touchpoint,' said an Esteworld spokesperson. 'Our London office brings those together. People can receive assessments, treatment planning, and follow-ups close to home, while their surgical journey remains anchored in our established Turkish hospitals.' A seamless UK-Turkey care pathway The London location is designed for consultations (not surgical procedures) so patients can meet a medical consultant, discuss candidacy, choose the most suitable hair transplant method, and understand the expected timeline before traveling. This model makes the experience more accessible for patients who prefer face-to-face guidance without sacrificing the standards and efficiencies that Turkey offers. A great opportunity for those who cannot have a hair transplant in London. In Istanbul, Esteworld performs procedures such as FUE (Follicular Unit Extraction), Sapphire FUE, DHI (Direct Hair Implantation), and unshaven approaches for qualifying candidates. Technique recommendations are individualized, taking into account donor density, hair caliber, curl pattern, hairline design goals, and long-term planning to maintain a natural look as hair loss progresses. About Esteworld Established in 1994, Esteworld is an international healthcare group specializing in hair transplantation, plastic surgery, medical aesthetics, and dental aesthetics. With a network spanning 35+ countries, Esteworld delivers end-to-end patient pathways through coordinated local offices and advanced hospital facilities. Esteworld's hair restoration portfolio includes FUE, Sapphire FUE, DHI, and suitable unshaven approaches, supported by standardized clinical protocols, donor management strategies, and natural hairline design principles. Multilingual patient coordination, transparent pricing structures, and comprehensive post-operative follow-up are integral to the group's service model. Combining high surgical experience with evidence-based practice and rigorous safety standards, Esteworld focuses on outcomes that look natural and remain sustainable over time. The group's integrated approach aligns medical necessity with aesthetic goals, providing patients a reliable, seamless, and internationally accessible care experience. Why Turkey remains a leader in hair transplantation Turkey's prominence in hair restoration stems from high surgical volumes, specialized teams, and a service model that streamlines logistics for international patients. Many clinics (Esteworld included also) organize airport transfers, translation assistance, and post-operative kits to reduce friction during a short medical stay. The combination of experience, coordinated care, and competitive pricing has drawn patients from around the world. About hair transplant prices in Turkey While pricing always depends on the clinic, technique, surgeon seniority, and graft count, Turkey is widely recognized for cost-effective options compared with Western Europe and North America. Patients commonly encounter two pricing structures: Because individual needs differ (some require 2,000 grafts, others 4,000 or more) final costs are best determined after a professional evaluation that considers donor capacity and long-term hair-loss patterns. Esteworld emphasizes transparent quoting so patients understand exactly what is included before traveling. What patients can expect with Esteworld Consultation & candidacy: At the London office, patients receive a structured assessment that reviews medical history, scalp condition, and donor area. The consultant discusses realistic outcomes, hairline philosophy, and potential graft counts, and sets expectations around the growth timeline. Technique selection: FUE and DHI are the most frequently recommended techniques. FUE involves extracting follicular units individually and implanting them into micro-channels; Sapphire FUE uses sapphire-tipped tools for channel creation; DHI places grafts with pen-like instruments that allow precise angle and direction. The goal is to harmonize density, direction, and hairline shape with each patient's unique features. Surgery in Istanbul: Procedures are performed by dedicated teams in Esteworld's Turkish hospitals, where standardized protocols govern anesthesia, sterile technique, graft handling, and recipient site creation. High case volumes help refine micro-surgical skills and consistency, supporting natural, age-appropriate results. Safety, ethics, and realistic expectations Hair transplantation is a medical procedure, not a commodity. Esteworld advocates for evidence-based practice and thorough informed consent. Not every patient is an ideal candidate. Donor limitations, diffuse thinning, scarring alopecia, or certain medical conditions may call for conservative plans or a staged approach. Adjunct therapies (including topical agents, oral medications when appropriate, low-level laser therapy, and PRP) may be discussed as part of a personalized long-term strategy. A natural outcome depends on more than graft numbers. Key variables include the hairline's anatomic placement, graft angulation, distribution in zones of visual priority, and respect for future hair-loss progression. Esteworld's planning process prioritizes long-term aesthetics to avoid an unnaturally dense front with inadequate reserves for later. The patient journey, step by step Value without compromise By originating in Turkey and later opening a London office, Esteworld aims to combine the best of both worlds: the experience and efficiencies that come from a leading hair transplant Turkey ecosystem, and the reassurance of local, ongoing support. For many, this hybrid model shortens decision time, clarifies expectations, and maintains continuity from first conversation to final results. 'Patients deserve clarity,' the Esteworld spokesperson added. 'Our approach is to explain the medical reasoning, set goals that make sense for the long term, and deliver attentive aftercare. Opening in London lets us do even more of that, face-to-face.' Media Details : Name: Burak Tuncer E-mail: [email protected] Phone number: +90 216 474 54 54 Web: SOURCE: Burak Tuncer press release
